Psychedelic Spotlight
  • News
  • Culture
  • Business
    • Business
    • News
    • Editorial
    • Stock Reports
    • Videos
    • Interviews
  • Research
  • Policy
  • Media
    • Podcast
    • Videos
  • Work With us
    • Work With Us
    • Contact Us
    • About
  • Media Kit
  • Bonfire Community
    • Work with us
  • Search
  • Menu Menu
Home1 / Psychedelic Spotlight News2 / Business3 / Stock Reports4

Psychedelic Business Spotlight – May 6

byGreg GilmanonMay 6, 2022
  • Share on Facebook
  • Share on Twitter
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn

This week in psychedelic business news: Wesana Health pivots strategy; Compass Pathways makes progress on anorexia; Completion launches psychedelic VR NFTs.

Wesana Health May Sell Clinics to Focus Solely on Drug Development

Leading this week's psychedelic business news, Wesana Health (CSE: WESA; OTCQB: WSNAF) announced a strategic review of Wesana’s care delivery division “including, but not limited to, a sale of all the assets” under that umbrella which includes two Chicago clinics, its Wesana Solutions platform, and PsyTech Connect. “Over the past year, we have grown two distinct divisions reflecting our novel paradigm of care development and care delivery,” said founder and CEO Daniel Carcillo. “This approach served the Company well and allowed us to bring leading edge therapies to individuals in need of care while driving forward a sophisticated drug development program. As we plan for our next milestone of an expanded lead indication for SANA-013 consistent with the positive feedback from FDA, it is now time to streamline our focus to accelerate the development of SANA-013, including initiation of a Phase 1b/2a human study for Major Depressive Disorder in H1 2023.” Read our Psychedelic Invesstor's full analysis of what this means for the company and industry at large.

Compass Pathways Makes Strides in Anorexia Research

Anorexia still does not have an FDA-approved treatment. Could psilocybin one day fill that void? Compass Pathways (Nasdaq: CMPS) shared promising study results this week that indicate its COMP360 psilocybin therapy may be beneficial for those suffering from anorexia. A 10-person trial conducted by Dr. Walter Kaye at the University of California San Diego School of Medicine found a single 25mg dose of the psychedelic drug led to 30% experiencing clinically significant reductions in eating disorder psychopathology at the 1-month follow up, and 40% experiencing clinically significant reductions at the 3-month follow-up. Overall, nine of the 10 subjects studied found the experience to be meaningful and therapeutic, and no serious adverse events were reported. “The results provide promising preliminary evidence that COMP360 psilocybin therapy could help people living with anorexia nervosa,” says Dr. Guy Goodwin, the company's Chief Medical Officer. Though, he adds, the company’s confidence in the potential to treat the condition “needs to be further investigated in larger scale clinical studies.”

Related Posts

The Biggest Psychedelic News Stories of the Week – June 3

Trip Do's and Don'ts: What to Avoid During Your Psychedelic Experience

The Largest Phase 3 Trial on Psilocybin for Depression Has Kicked Off

Single Dose of Psilocybin Yields Long-Term Depression Remission in Over 50% of Cancer Patients

Completion to Launch Psychedelic VR NFTs on May 25

Danish NFT startup Completion is set to release 10-minute psychedelic plug and play virtual reality NFTs, with the potential to combat depression and stress, on May 25 through the Completion VR app by owners of the Genesis NFTs. “We’re using groundbreaking technology in the Generative Art & NFT spaces to create virtual reality experiences that fully immerse you into the music & fractal art of these experiences,” says founder & CEO Andreas D. Christiansen. “Completion essentially simulates the ‘mind blowing' psychedelic experiences that many people have historically otherwise had to obtain drugs to search and explore.”

Tripsitter Gets a 2022 Refresh

Lastly in this week's psychedelic business spotlight, Tripsitter, a psychedelic business in the media space, refreshed its entire look and feel for 2022 this month, now featuring over 100 psychedelic monographs along with various harm-reduction guides, biographies, and a directory of vetted retreat centers, and training programs. The site has been overhauled and optimized for a better user experience, incorporates psychedelic-inspired artwork, and offers brand-new content on the topics of philosophy and neuroscience. “Our goal is to provide the resources necessary to demystify these substances and give our readers the tools to use them effectively,” says creative director Justin Cooke. “We see psychedelics as a catalyst for change, something the world needs now more than ever.”

Have you heard about our new community?

We’re excited to announce Bonfire -
a personal growth community
for people who are interested in psychedelics.

Join us for our launch event on July 18th, where we’ll share about the work we’ll be doing together to actualize our personal missions, grow, and heal together.

Sign Up Here
0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *

Related News

Compass Pathways Appoints a New CEO

Compass Pathways Appoints a New CEO

Business, News
George Goldsmith will be replaced as Compass Pathways CEO. Is this good or bad news?
0 Comments
/
July 19, 2022

Psychedelic Business Spotlight – May 27

Business, Stock Reports
This week in psychedelic business news: New patents; another Health Canada SAP Approval; and legal psilocybin rules for Oregon.
0 Comments
/
May 27, 2022
race and ethnicity in psychedelics

How Does Race and Ethnicity Influence Psychedelic Mental Health Outcomes? 

Research
Psychedelic therapy is growing in popularity, but clinical trials often overlooks the unique needs of diverse racial and ethnic populations
3 Comments
/
November 1, 2022

Psychedelic Spotlight is your reliable source for the latest stories in the emerging psychedelics industry, covering breakthrough discoveries, investor news and cultural reform.

Explore

  • About
  • Treatment
  • Work With Us
  • News
  • Privacy Policy
  • Terms and Conditions

Resources

  • Conferences
  • Experts
  • Glossary
  • Therapy

Subscribe

           

© 2022 Psychedelic Spotlight. | Owned and operated by PSYC Media Corporation, Inc. a US publicly traded company (OTCPink: PSYC) | All Rights Reserved.
Wesana Health May Sell Clinics to Focus Solely on Drug Development: An Anal...Wesana Health May Sell Clinics to Focus Solely on Drug DevelopmentShutterstockPsychedelics, Neuroscience & Big Pharma – Interview with Rob Barrow...
Scroll to top

Get a roundup of Psychedelic news stories in your inbox

By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.

Hidden
Which list would you like to subscribe to?
Enter your email below to subscribe to Psychedelic News.